Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
Joint Authors
Source
Issue
Vol. 2008, Issue 2008 (31 Dec. 2008), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2008-07-16
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating both glucose and lipid metabolism.
Agonists for both PPARγ and PPARγ have been used to treat dyslipidemia and hyperglycemia, respectively.
In addition to affecting glucose metabolism, PPARγ agonists also regulate lipid metabolism.
In this review, we will focus on the randomized clinical trials that directly compared the lipid effects of the thiazolidinedione class of PPARγ agonists, pioglitazone and rosiglitazone, head-to-head either as monotherapy or in combination with other lipid-altering or glucose-lowering agents
American Psychological Association (APA)
Deeg, Mark A.& Tan, Meng H.. 2008. Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies. PPAR Research،Vol. 2008, no. 2008, pp.1-6.
https://search.emarefa.net/detail/BIM-988211
Modern Language Association (MLA)
Deeg, Mark A.& Tan, Meng H.. Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies. PPAR Research No. 2008 (2008), pp.1-6.
https://search.emarefa.net/detail/BIM-988211
American Medical Association (AMA)
Deeg, Mark A.& Tan, Meng H.. Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies. PPAR Research. 2008. Vol. 2008, no. 2008, pp.1-6.
https://search.emarefa.net/detail/BIM-988211
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-988211